RETRACTED: Aescusan: pharmacology, pharmacokinetics and therapeutic characteristics
https://doi.org/10.21518/1995-1477-2019-1-2-19-25
Abstract
The article is devoted to Aescusan, a well-studied preparation that is traditionally used in clinical practice for the treatment of chronic diseases of veins, hemorrhoids, postoperative and post-traumatic edema. The main active substance is aescin that is contained in horse chestnut seed extract - Aesculus hippocastanum. The paper presents data of a randomized controlled study demonstrating the efficacy of Aescusan in the treatment of chronic venous diseases and chronic venous edema along with the compression therapy. A number of in vitro and in vivo experimental studies provided convincing proof of efficacy of Aescusan. In particular, they proved the anti-edema, anti-inflammatory and venotonic effect of the preparation. Aescusan improves calcium ions entry into the smooth muscle cell channels in the vascular wall, which increases the venous vascular tone. The anti-inflammatory effect of Aescusan is associated with blockade of prostaglandin F2 (PGF2) release from the venous wall, 5-hydroxytryptamine (5-HT) and histamine antagonism, decreased catabolism of tissue mucopolysaccharides. Conclusion: Aescusan has a pluripotent effect on various pathogenetic mechanisms of chronic venous diseases. It is known for its good tolerability and ease of use, which makes it possible to use the preparation in patients with chronic venous diseases, hemorrhoids, and peripheral post-traumatic edema.
About the Authors
V. Yu. Bogachev
Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation; First Phlebological Center
Russian Federation
Russian Federation
Bogachev Vadim Yurievich – Dr. of Sci. (Med), Professor of the Department of Faculty Surgery No. 2 of the Pirogov National Research Medical Universityof the Ministry of Health of the Russian Federation; Scientific Director of the First Phlebological Center.
117997, Moscow, Ostrovityanova St., 1; 117447, Moscow, Dmitry Ulyanov Street, 31; tel.: +7 (499) 955-44-53.
B. V. Boldin
Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Boldin Boris Valentinovich - Dr. of Sci. (Med.), Professor, Head of Chair of Faculty Surgery No. 2.
117997, Moscow, Ostrovityanova St., 1.
O. V. Dzhenina
First Phlebological Center
Russian Federation
Russian Federation
Dzhenina Olga Vadimovna - Cand. of Sci. (Med.), Phlebologist.
117447, Moscow, Dmitry Ulyanov Street, 31; tel.: +7 (495) 967-94–42.
References
1. Naoum J.J., Hunter G.C. Pathogenesis of Varicose Veins and Implications for Clinical Management. Vascular. 2007;15(5):242–249.
2. Sirtori C.R. Aescin: pharmacology, pharmacokinetics and therapeutic profile. Pharmacol Res. 2001;44:183–193.
3. Dudek-Makuch M., Studzinska-Sroka E. Horse chestnutefficacy and safety in chronic venous insufficiency: an overview. Revista Brasileira de Farmacognosia. 2015;25:533-541.
4. Perrin M., Ramelet A.A. Pharmacological Treatment of Primary Chronic Venous Disease: Rationale, Results and Unanswered Questions. Eur. J. Vasc. Endovasc. Surg. 2011;41:117–25.
5. Diehm C., Trampisch H.J., Lange S., Schmidt C. Comparison of leg compression stocking and oral horse-chestnut seed extract therapy in patients with chronic venous insufficiency. Lancet. 1996;347(8997):292–294.
6. Handbook of venous disorders (4th edition). Guidelines of the American Venous Forum edited by P. Gloviczki, 2017.
7. Management of chronic venous disorders of the lower limbs. Guidelines according to scientific evidence. Part I. International Angiology. 2018;37(3):181-254.
Review
For citations:
Bogachev V.Yu., Boldin B.V., Dzhenina O.V. RETRACTED: Aescusan: pharmacology, pharmacokinetics and therapeutic characteristics. Ambulatornaya khirurgiya = Ambulatory Surgery (Russia). 2019;(1-2):19-25. (In Russ.) https://doi.org/10.21518/1995-1477-2019-1-2-19-25
Views:
14227
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International.
Email this article 